TW201625284A - 新穎的雷曼氏乳桿菌菌株（ｌａｃｔｏｂａｃｉｌｌｕｓ ｒｈａｍｎｏｓｕｓ）與其用於抑制黃嘌呤氧化酶及治療痛風之代謝產物 - Google Patents
新穎的雷曼氏乳桿菌菌株（ｌａｃｔｏｂａｃｉｌｌｕｓ ｒｈａｍｎｏｓｕｓ）與其用於抑制黃嘌呤氧化酶及治療痛風之代謝產物 Download PDFInfo
- Publication number
- TW201625284A TW201625284A TW104127381A TW104127381A TW201625284A TW 201625284 A TW201625284 A TW 201625284A TW 104127381 A TW104127381 A TW 104127381A TW 104127381 A TW104127381 A TW 104127381A TW 201625284 A TW201625284 A TW 201625284A
- Authority
- TW
- Taiwan
- Prior art keywords
- composition
- lactobacillus
- lactobacillus reuteri
- uric acid
- agent
- Prior art date
Links
- 102100033220 Xanthine oxidase Human genes 0.000 title claims abstract description 28
- 108010093894 Xanthine oxidase Proteins 0.000 title claims abstract description 28
- 239000002207 metabolite Substances 0.000 title claims abstract description 12
- 241000218588 Lactobacillus rhamnosus Species 0.000 title claims abstract description 7
- 201000005569 Gout Diseases 0.000 title claims description 5
- 230000002401 inhibitory effect Effects 0.000 title abstract description 15
- 239000000203 mixture Substances 0.000 claims abstract description 62
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 claims abstract description 33
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 claims abstract description 33
- 238000000034 method Methods 0.000 claims abstract description 33
- 229940116269 uric acid Drugs 0.000 claims abstract description 33
- 238000012258 culturing Methods 0.000 claims abstract description 13
- 238000004519 manufacturing process Methods 0.000 claims abstract description 4
- 241000186604 Lactobacillus reuteri Species 0.000 claims description 23
- 229940001882 lactobacillus reuteri Drugs 0.000 claims description 22
- 241000186660 Lactobacillus Species 0.000 claims description 20
- 229940039696 lactobacillus Drugs 0.000 claims description 20
- 230000000694 effects Effects 0.000 claims description 9
- 239000003795 chemical substances by application Substances 0.000 claims description 8
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 7
- 239000000796 flavoring agent Substances 0.000 claims description 6
- 235000013336 milk Nutrition 0.000 claims description 6
- 239000008267 milk Substances 0.000 claims description 6
- 210000004080 milk Anatomy 0.000 claims description 6
- 239000000843 powder Substances 0.000 claims description 6
- 201000001431 Hyperuricemia Diseases 0.000 claims description 5
- 235000013355 food flavoring agent Nutrition 0.000 claims description 4
- 238000004108 freeze drying Methods 0.000 claims description 4
- 239000000872 buffer Substances 0.000 claims description 3
- 239000003085 diluting agent Substances 0.000 claims description 3
- 238000001914 filtration Methods 0.000 claims description 3
- 229920000642 polymer Polymers 0.000 claims description 3
- 239000003381 stabilizer Substances 0.000 claims description 3
- 230000001954 sterilising effect Effects 0.000 claims description 3
- 239000000853 adhesive Substances 0.000 claims description 2
- 230000001070 adhesive effect Effects 0.000 claims description 2
- 239000003963 antioxidant agent Substances 0.000 claims description 2
- 230000003078 antioxidant effect Effects 0.000 claims description 2
- 239000011230 binding agent Substances 0.000 claims description 2
- 239000011248 coating agent Substances 0.000 claims description 2
- 239000003995 emulsifying agent Substances 0.000 claims description 2
- 235000012041 food component Nutrition 0.000 claims description 2
- 235000003599 food sweetener Nutrition 0.000 claims description 2
- 239000003112 inhibitor Substances 0.000 claims description 2
- 239000000314 lubricant Substances 0.000 claims description 2
- 235000020939 nutritional additive Nutrition 0.000 claims description 2
- 238000009928 pasteurization Methods 0.000 claims description 2
- 239000012748 slip agent Substances 0.000 claims description 2
- 238000004659 sterilization and disinfection Methods 0.000 claims description 2
- 239000003765 sweetening agent Substances 0.000 claims description 2
- 239000002562 thickening agent Substances 0.000 claims description 2
- 235000015203 fruit juice Nutrition 0.000 claims 2
- 239000005428 food component Substances 0.000 claims 1
- 239000003906 humectant Substances 0.000 claims 1
- 239000003755 preservative agent Substances 0.000 claims 1
- 230000002335 preservative effect Effects 0.000 claims 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 18
- 239000002609 medium Substances 0.000 description 16
- 241000894006 Bacteria Species 0.000 description 14
- 239000004310 lactic acid Substances 0.000 description 9
- 235000014655 lactic acid Nutrition 0.000 description 9
- LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical compound O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 description 8
- 240000001929 Lactobacillus brevis Species 0.000 description 7
- 235000013957 Lactobacillus brevis Nutrition 0.000 description 7
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 238000000855 fermentation Methods 0.000 description 6
- 230000004151 fermentation Effects 0.000 description 6
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 5
- 230000005764 inhibitory process Effects 0.000 description 5
- 238000002255 vaccination Methods 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 4
- 235000013305 food Nutrition 0.000 description 4
- 239000002953 phosphate buffered saline Substances 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 229940075420 xanthine Drugs 0.000 description 4
- 239000003064 xanthine oxidase inhibitor Substances 0.000 description 4
- 108020004465 16S ribosomal RNA Proteins 0.000 description 3
- PLLBRTOLHQQAQQ-UHFFFAOYSA-N 8-methylnonan-1-ol Chemical compound CC(C)CCCCCCCO PLLBRTOLHQQAQQ-UHFFFAOYSA-N 0.000 description 3
- 235000004936 Bromus mango Nutrition 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 239000004440 Isodecyl alcohol Substances 0.000 description 3
- 240000007228 Mangifera indica Species 0.000 description 3
- 235000014826 Mangifera indica Nutrition 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- IAPCTXZQXAVYNG-UHFFFAOYSA-M Potassium 2,6-dihydroxytriazinecarboxylate Chemical compound [K+].[O-]C(=O)C1=NC(=O)NC(=O)N1 IAPCTXZQXAVYNG-UHFFFAOYSA-M 0.000 description 3
- 235000009184 Spondias indica Nutrition 0.000 description 3
- 108010092464 Urate Oxidase Proteins 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 235000019674 grape juice Nutrition 0.000 description 3
- 235000015205 orange juice Nutrition 0.000 description 3
- 229950000193 oteracil Drugs 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 229940124597 therapeutic agent Drugs 0.000 description 3
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 241000186000 Bifidobacterium Species 0.000 description 2
- 241001608472 Bifidobacterium longum Species 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 241000186840 Lactobacillus fermentum Species 0.000 description 2
- 241000186606 Lactobacillus gasseri Species 0.000 description 2
- 241000186605 Lactobacillus paracasei Species 0.000 description 2
- 241000186684 Lactobacillus pentosus Species 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 102000004316 Oxidoreductases Human genes 0.000 description 2
- 108090000854 Oxidoreductases Proteins 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 2
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 229940123769 Xanthine oxidase inhibitor Drugs 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 238000009634 analytical profile index Methods 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 229940009291 bifidobacterium longum Drugs 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 235000010633 broth Nutrition 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 210000003608 fece Anatomy 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 208000017169 kidney disease Diseases 0.000 description 2
- 229940012969 lactobacillus fermentum Drugs 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 235000010356 sorbitol Nutrition 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- DIIIISSCIXVANO-UHFFFAOYSA-N 1,2-Dimethylhydrazine Chemical compound CNNC DIIIISSCIXVANO-UHFFFAOYSA-N 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- KHPWHSXHIVVNRI-UHFFFAOYSA-N 4-amino-2,5-dihydro-1h-pyrazolo[3,4-d]pyrimidine-3,6-dione Chemical compound NC1=NC(O)=NC2=C1C(=O)NN2 KHPWHSXHIVVNRI-UHFFFAOYSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 208000013824 Acidemia Diseases 0.000 description 1
- 208000010444 Acidosis Diseases 0.000 description 1
- 241000178564 Agrobacterium aurantiacum Species 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 108010053835 Catalase Proteins 0.000 description 1
- 102100035882 Catalase Human genes 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 244000199866 Lactobacillus casei Species 0.000 description 1
- 235000013958 Lactobacillus casei Nutrition 0.000 description 1
- 241000186784 Lactobacillus oris Species 0.000 description 1
- 241000183331 Lactobacillus paracasei subsp. tolerans Species 0.000 description 1
- 241000577554 Lactobacillus zeae Species 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- 241000235070 Saccharomyces Species 0.000 description 1
- 241000207929 Scutellaria Species 0.000 description 1
- 102000007562 Serum Albumin Human genes 0.000 description 1
- 108010071390 Serum Albumin Proteins 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 206010000059 abdominal discomfort Diseases 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 239000008351 acetate buffer Substances 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 238000010306 acid treatment Methods 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 125000005907 alkyl ester group Chemical group 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 235000015241 bacon Nutrition 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 235000013527 bean curd Nutrition 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 229960000074 biopharmaceutical Drugs 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 235000013877 carbamide Nutrition 0.000 description 1
- XNEYCQMMVLAXTN-UHFFFAOYSA-N carbonic acid;magnesium Chemical compound [Mg].OC(O)=O XNEYCQMMVLAXTN-UHFFFAOYSA-N 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 235000013351 cheese Nutrition 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 239000007979 citrate buffer Substances 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 239000002532 enzyme inhibitor Substances 0.000 description 1
- 229940125532 enzyme inhibitor Drugs 0.000 description 1
- 235000019441 ethanol Nutrition 0.000 description 1
- 235000019264 food flavour enhancer Nutrition 0.000 description 1
- 239000005417 food ingredient Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 235000015243 ice cream Nutrition 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 239000002054 inoculum Substances 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 229940017800 lactobacillus casei Drugs 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 201000002364 leukopenia Diseases 0.000 description 1
- 231100001022 leukopenia Toxicity 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 229940040145 liniment Drugs 0.000 description 1
- 239000000865 liniment Substances 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 239000000395 magnesium oxide Substances 0.000 description 1
- CPLXHLVBOLITMK-UHFFFAOYSA-N magnesium oxide Inorganic materials [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 description 1
- 235000012245 magnesium oxide Nutrition 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- AXZKOIWUVFPNLO-UHFFFAOYSA-N magnesium;oxygen(2-) Chemical compound [O-2].[Mg+2] AXZKOIWUVFPNLO-UHFFFAOYSA-N 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000004899 motility Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 235000011007 phosphoric acid Nutrition 0.000 description 1
- 235000021110 pickles Nutrition 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 239000006041 probiotic Substances 0.000 description 1
- 230000000529 probiotic effect Effects 0.000 description 1
- 235000018291 probiotics Nutrition 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 235000021108 sauerkraut Nutrition 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 210000003802 sputum Anatomy 0.000 description 1
- 208000024794 sputum Diseases 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 206010043554 thrombocytopenia Diseases 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 241000556533 uncultured marine bacterium Species 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 235000013618 yogurt Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/38—Other non-alcoholic beverages
- A23L2/382—Other non-alcoholic beverages fermented
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/745—Bifidobacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/062—Ascomycota
- A61K36/064—Saccharomycetales, e.g. baker's yeast
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
- C12N1/205—Bacterial isolates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/0004—Oxidoreductases (1.)
- C12N9/0093—Oxidoreductases (1.) acting on CH or CH2 groups (1.17)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P1/00—Preparation of compounds or compositions, not provided for in groups C12P3/00 - C12P39/00, by using microorganisms or enzymes
- C12P1/04—Preparation of compounds or compositions, not provided for in groups C12P3/00 - C12P39/00, by using microorganisms or enzymes by using bacteria
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/52—Adding ingredients
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/175—Rhamnosus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/02—Separating microorganisms from their culture media
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/70—Undefined extracts
- C12N2500/72—Undefined extracts from bacteria
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
- C12R2001/225—Lactobacillus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y117/00—Oxidoreductases acting on CH or CH2 groups (1.17)
- C12Y117/03—Oxidoreductases acting on CH or CH2 groups (1.17) with oxygen as acceptor (1.17.3)
- C12Y117/03002—Xanthine oxidase (1.17.3.2)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Mycology (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Nutrition Science (AREA)
- Molecular Biology (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Biomedical Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Virology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Physiology (AREA)
- Medical Informatics (AREA)
- Alternative & Traditional Medicine (AREA)
- Botany (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Pain & Pain Management (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
一種用於抑制黃嘌呤氧化酶及用於降低尿酸位準的方法，該方法係使用一種藉由於一培養基中培養雷曼氏乳桿菌(Lactobacillus rhamnosus)所獲得的組成物。此處亦揭示一種用於降低一個體中之尿酸位準的組成物，其包括一雷曼氏乳桿菌代謝產物；以及一種用於製造該組成物之方法。
Description
本申請案主張於2014年8月22日所提出之美國臨時申請案序號第62/040616號的利益。該申請案之內容在此以其整體併入以為參考資料。
本發明係關於藉由乳酸菌及其發酵代謝產物來抑制黃嘌呤氧化酶活性。
尿酸是體內嘌呤代謝的最終產物。於血液中之高位準之尿酸會導致尿酸結晶在關節、腎臟及其他器官中形成及沉澱。高於7mg/dL之血液尿酸濃度被認為是高尿酸血症(hyperuricemia)。
高尿酸血症是一種常見的代謝失調，其與痛風、高血壓、心血管疾病、糖尿病及腎臟病有關聯。一項從1993年至2008年在台灣所進行的流行病學調查指出，呈現高尿
酸血症的男性與女性病患的百分比各別為21.6%及9.57%。
黃嘌呤氧化酶在尿酸的合成中是一種關鍵酵素。因此，抑制黃嘌呤氧化酶活性可降低尿酸的產生。確實，黃嘌呤氧化酶抑制劑(即尿酸酶)對於減低血液中的尿酸濃度是有效的。尿酸酶是一種在人類中未被發現的酵素。其典型地被分離為一重組哺乳動物蛋白質，並藉由靜脈輸注(IV infusion)來投予。就此而言，尿酸酶之製造可能是昂貴的且其投藥可能是困難的。
異嘌呤醇也是一種黃嘌呤氧化酶抑制劑。此化合物是於臨床上投予以減低血清之尿酸位準。然而，異嘌呤醇具有副作用，諸如過敏性反應、腸胃不適、白血球減少症及血小板減少症、肝炎、腎病變以及6-硫醇嘌呤毒性，其於某些案例中可能導致死亡。
有鑒於用於高尿酸血症之現存療法的缺點，許多生物製藥公司聚焦於開發新的尿酸減低藥劑。例如，Izumida等人從海洋細菌橙黃農桿菌(Agrobacterium aurantiacum)中分離出一種可減低尿酸位準的化合物，亦即羥阿卡酮(hydroxyakalone)(J.Antibiotics 50：916-918)。
其他微生物物種亦已顯示出具有尿酸減低能力，該等微生物物種包含發酵乳桿菌(Lactobacillus fermentum)、戊糖乳桿菌(Lactobacillus pentosus)、加氏乳桿菌(Lactobacillus gasseri)、口乳桿菌(Lactobacillus oris)、長雙歧桿菌(Bifidobacterium longum)、以及釀酒酵母菌(Saccharomyces cerevisiae)之菌株。參見，例如，美國專利
申請案公開號2010/0316618、2011/0014168及2013/0330299；以及歐洲專利申請案公開號2457576及1649863。
對於從天然來源開發出可簡單製造且安全投予之新黃嘌呤氧化酶抑制劑的需求仍然存在。
為滿足此需求，本發明提供藉由乳酸菌所製造的黃嘌呤氧化酶抑制劑。
本發明也提供一種用於抑制黃嘌玲氧化酶的方法。該方法包括下列步驟：於一培養基中培養雷曼氏乳桿菌(Lactobacillus rhamnosus)以形成一組成物，以及令該黃嘌呤氧化酶與該組成物接觸。
本發明亦揭示一種用於降低一個體中之尿酸位準的方法，該方法包括於一培養基中培養雷曼氏乳桿菌以形成一組成物，以及將該組成物投予至一具有升高之尿酸位準的個體。所投予之量對於降低尿酸位準是有效的。
於本發明之範圍內的是一種用於製造用以降低一個體中之尿酸位準之組成物的方法。該方法是藉由將一培養基接種雷曼氏乳桿菌，並於該培養中培養雷曼氏乳桿菌以形成一組成物。
本發明進一步揭示一種用於降低一個體中之尿酸位準的組成物。該組成物包括雷曼氏乳桿菌之一代謝產物。
本發明之一或多個實施態樣的細節將於下面詳細說明及實施例中闡明。本發明之其餘特徵、目的以及優點將從數個實施態樣之詳細說明中以及亦從請求項中變得明顯。所有於此引用之出版物及專利文件以其整體併入本案以為參考資料。
如上面所提及的，所揭示的是一種藉由投予一含有雷曼氏乳桿菌之組成物來降低一個體中之尿酸位準的方法。於一特別實施態樣中，該雷曼氏乳桿菌係雷曼氏乳桿菌I21，其寄存編號為DSM 28876。
於一實施態樣中，該個體是高尿酸血症者。於其它實施態樣中，該個體患有痛風。
該如上所述之方法包括藉由於一培養基中培養雷曼氏乳桿菌來形成一組成物之一步驟。該培養基可為，但不限於，MRS肉湯(de-Man-Rogosa-Sharpe broth)、牛奶及果汁。於特定實施態樣中，該培養基是葡萄汁、芒果汁或柳橙汁。於一特別實施態樣中，該方法包括在培養後且在投予該組成物前從該培養基中移除雷曼氏乳桿菌之一步驟。
上述之組成物可藉由數種途徑局部性或全身性投予，該等途徑包含，但不限於，肌內、皮內、靜脈內、
皮下、腹膜內、鼻內、口服、黏膜以及外部。
取決於投藥之途徑，該組成物可以各種方式被配製。例如，該組成物可為一液體溶液、一懸浮液、一乳化液、一糖漿、一錠劑、一丸劑、一膠囊、一延遲釋放調配物、一粉劑、一顆粒、一安瓿、一注射劑、一輸注劑(infusion)、一套組、一軟膏、一洗劑、一擦劑、一乳霜或其等之一組合。該組成物可被滅菌或與一藥學上可接受之載體或賦形劑混合。
如此處所使用之術語「載劑」或「賦形劑」意指任何物質(本身非一治療劑)被用作為一載劑、稀釋劑、佐劑或媒介物(vehicle)，其(i)用於輸送一治療劑至一個體、(ii)用於添加至一調配物中以改善其處理或儲存性質及/或(iii)用以促進一劑量單位之組成物形成至一分立物品內，諸如適於口服投予之一膠囊或錠劑。
適合之載劑或賦形劑是製造藥學配方或食物產品之技藝中所熟知的。載劑或賦形劑可包括，作為例示說明且不限於，緩衝劑、稀釋劑、崩散劑、結著劑(binding agent)、黏著劑(adhesive)、濕潤劑、聚合物、潤滑劑、滑動劑、被加入以掩飾或抵消一不良口味或氣味的物質、調味劑、色素、香料，以及被加入以改善該組成物之外觀的物質。
可接受之載劑或賦形劑包括檸檬酸鹽緩衝劑、磷酸鹽緩衝劑、醋酸鹽緩衝劑、碳酸氫鹽緩衝劑、硬脂酸、硬脂酸鎂、氧化鎂、磷酸或硫酸之鈉鹽或鈣鹽、碳酸
鎂、滑石、明膠、阿拉伯膠、褐藻酸鈉、果膠、糊精、甘露醇、山梨醇、乳糖、蔗糖、澱粉、纖維素材料(例如，烷酸之纖維素酯以及纖維素烷基酯)、低熔點石蠟可可脂、胺基酸、尿素、醇類、抗壞血酸、磷脂質、蛋白質(例如，血清白蛋白)、乙二胺四醋酸(EDTA)、二甲亞碸(DMSO)、氯化鈉或其他鹽類、微脂體、甘露醇、山梨醇、甘油或粉末、聚合物(例如，聚乙烯氫吡咯酮、聚乙烯醇及聚乙二醇)，以及其他藥學上可接受之材料。該載劑不會破壞治療劑的藥理活性，且當以足夠輸送一治療量之藥劑的劑量投予時，該載劑為無毒性的。
所投予之該組成物之量對於降低個體中之尿酸濃度是有效的。一熟習此藝者可輕易地藉由例如計算該個體血液中尿酸濃度之改變來決定該有效量。
上述之用於抑制黃嘌呤氧化酶的方法包括於一培養基中培養雷曼氏乳桿菌以形成一組成物的步驟。於一較佳實施態樣中，該雷曼氏乳桿菌係雷曼氏乳桿菌I21，其寄存編號為DSM 28876。
該培養基可為，但不限於，MRS肉湯、牛奶及果汁。於一特定實施態樣中，該培養基是葡萄汁、芒果汁或柳橙汁。於一特別實施態樣中，該方法包括冷凍乾燥該組成物以形成一粉末之一步驟。
用於抑制黃嘌呤氧化酶之方法也包括將黃嘌呤氧化酶與上述之組成物接觸之一步驟。於一實施態樣中，該接觸步驟可於體外(in vitro)執行。例如，一黃嘌呤氧化
酶之製品可與該組成物一起放置於一容器中。於一實施態樣中，該接觸步驟之執行是藉由口服投予該組成物至一具有黃嘌呤氧化酶之個體。
上面概述的是一種用於製造用以降低一個體中之尿酸位準之一組成物的方法。該組成物是藉由首先將一培養基接種雷曼氏乳桿菌來製造。於一特定實施態樣中，該雷曼氏乳桿菌係雷曼氏乳桿菌I21，其寄存編號為DSM 28876。
用於接種該雷曼氏乳桿菌的培養基可為，但不限於，MRS肉湯、牛奶及果汁。於某些實施態樣中，該培養基是葡萄汁、芒果汁或柳橙汁。
在將該培養基接種雷曼氏乳桿菌之後，該經接種之培養基被進行培養，從而形成該用於降低一個體中之尿酸位準之組成物。該培養步驟可於37℃下實行。此外，該培養步驟可在兼性厭氣條件下實行。於一實施態樣中，該培養是執行2天。
藉由於一培養基中培養雷曼氏乳桿菌所獲得之組成物可藉由下列方法來滅菌，包括但不限於，巴斯德消毒法(pasteurization)、照射滅菌、高壓滅菌釜或過濾。例如，該組成物可藉由通過一為0.2μm的過濾器之過濾來予以滅菌。於一特別較佳實施態樣中，該經滅菌之液體肉湯是先被過濾或離心以移除該細菌，然後予以濃縮。
用於製造一用以降低一個體中之尿酸位準之組成物的方法可包括從該組成物中移除該雷曼氏乳桿菌之一
步驟。該雷曼氏乳桿菌於該移除步驟之前可具有一為1 x 108至1 x 109個細胞/ml之細胞密度。於一較佳實施態樣中，該雷曼氏乳桿菌之細胞密度於移除其等之前為1 x 109個細胞/ml。
於其它實施態樣中，該方法包括冷凍乾燥該組成物以形成一粉末之一步驟。
如上述之用於降低一個體中之尿酸位準的組成物包括雷曼氏乳桿菌之一代謝產物。該代謝產物是一種黃嘌呤氧化酶活性的抑制劑。於一特別實施態樣中，該代謝產物可為寄存編號為DSM 28876之雷曼氏乳桿菌I21之一代謝產物。
於一實施態樣中，該組成物可為一雷曼氏乳桿菌粉末。於一另擇的實施態樣中，該組成物中沒有雷曼氏乳桿菌。
於另一實施態樣中，除了該雷曼氏乳桿菌之代謝產物之外，該組成物可包括益生菌微生物，其等包括但不限於，乳桿菌屬菌株(Lactobacillus spp.)、雙歧桿菌屬菌株(Bifidobacterium spp.)以及酵母屬菌株(Saccharomyces spp.)。例如，發酵乳桿菌、戊糖乳桿菌、加氏乳桿菌、口乳桿菌、長雙岐桿菌以及釀酒酵母菌中之一或多者可被包括於該組成物中。
該組成物也可含有一或多種食物成分，例如，一著色劑、一酸度調節劑、一防結塊劑、一抗氧化劑、一增積劑、一載劑、一乳化劑、一增味劑、一包覆劑、一保存
劑、一安定劑、一甜味劑、一增稠劑、一營養添加劑及一調味劑。
於又另一實施態樣中，如上所述，該組成物包括一藥學可接受之賦形劑。
該組成物也可為一食物產品。例如，該組成物可為一優酪乳、一飲料、一冰淇淋或一乳酪。
無須進一步詳細闡述，相信熟習此藝者基於此處之揭示內容可將本發明利用至其最充分之程度。因此，以下特定實施例要被理解為僅說明之用，而非以任何方式侷限揭示內容的其餘部分。
34株乳酸菌菌株分別被接種至MRS培養盤上並於37℃下培養3天。細菌株是分離自健康嬰兒糞便、牛糞便、乳固形物、培根、豆腐乳、植物園土壤、醃菜及德國酸菜。細菌是使用一個1μl無菌接種環從每個培養盤刮下、接種至10ml之MRS肉湯中，並於37℃在兼性厭氣條件下培養1天以製備一接種原。該接種原隨後被加入至呈1%(v/v)之MRS肉湯中，並於37℃在兼性厭氣條件下培養1天。該培養基被離心，而上清液被收集用於黃嘌呤氧化酶抑制活性之分析。
黃嘌呤氧化酶抑制活性被測量如下。首先，來自每個菌株之10μl的培養基被加入至一個96-井培養盤中的一井。然後，150μl的50mM磷酸鹽緩衝鹽水液(PBS)及
80μl的150mM黃嘌呤被加入至每一井中。在將10μl的黃嘌呤氧化酶(0.1U)加入至每一井之前，於290nm下測定一初始吸收值(OD之前)。在25℃下培養該培養盤30分鐘之後，再次測量於290nm下的吸收值(OD之後)。每個樣本之黃嘌呤氧化酶抑制活性(XOI)是依據下列公式來計算：
結果顯示於下面表1中。在所測試的34株乳酸菌菌株中，有2株菌株[亦即，菌株I21及菌株F73(以斜體字顯示)]抑制黃嘌呤氧化酶活性超過40%。
乳酸菌菌株F73及I21被接種至MRS培養盤上並於37℃下培養3天。該等細菌是以一個1μl無菌接種環從該培養盤刮下、接種至MRS肉湯中，並於37℃下培養1天以製備一接種原。該接種原隨後被加入至MRS肉湯中並於37℃下培養歷時長達7天。樣本於第1天、第2天及第7天之培
養中移出、離心，而上清液被收集用於黃嘌呤氧化酶抑制活性之分析。
於一反應管中，880μl的黃嘌呤(50μg/ml，配於100mM PBS中)及40μl的50mM PBS或40μl的該培養上清液被預混合，且80μl的黃嘌呤氧化酶(0.1U)被加入以起始反應。該反應於30℃下培養30分鐘，在培養後，加入一等體積之無水乙醇以終止該反應。該經終止之反應透過一為0.25μm之膜過濾器來過濾，而黃嘌呤之含量藉由HPLC來分析。該等樣本之黃嘌呤氧化酶抑制活性是依據下列公式來計算：
結果顯示於下面表2中。
a樣本在該培養天數被移出
b數值是以黃嘌呤氧化酶活性之抑制百分比來表示
該等結果證實乳酸菌菌株I21的黃嘌呤氧化酶抑制活性高於菌株F73。值得注意的是，菌株I21之黃嘌呤氧化酶抑制活性在發酵1天後達到最大值。延長菌株I21之培養歷時長達7天不會致使黃嘌呤氧化酶抑制活性之增加。
乳酸菌菌株I21是分離自一健康嬰兒之糞便。此
菌株之一分析顯示出其為革蘭氏陽性、過氧化氫酶及氧化酶陰性，以及不具運動性。此外，該菌株不會製造內孢子且可生長於好氣及兼性厭氣這兩種條件下。
來自菌株I21的16s rDNA序列(序列辨識編號：1)被分析且被認定是與乾酪乳桿菌(Lactobacillus casei)、副乾酪乳桿菌副乾酪亞種(Lactobacillus paracasei subsp.Paracasei)、副乾酪乳桿菌堅韌亞種(Lactobacillus paracasei subsp.Tolerans)、雷曼氏乳桿菌以及玉米乳桿菌(Lactobacillus zeae)最相似。該16s rDNA序列之相似度高達98%。
DnaK基因之一部份序列(序列辨識編號：2)的分析顯示出菌株I21與雷曼氏乳桿菌共享99%序列一致性。
使用analytical profile index API®鑑定系統，菌株I21也具有關於發酵某些醣類之能力的特性。此試驗顯示出菌株I21是雷曼氏乳桿菌之一菌株。
申請人依據布達佩斯條約在2014年6月2日將雷曼氏乳桿菌菌株I21寄存於國際菌株寄存機構萊布尼茲研究所DSMZ-德國微生物及細胞培養物收集中心(Inhoffenstr.7 B,D-38124 Braunschweig GERMANY)。該菌株被指定之寄存編號為DSM 28876。
雷曼氏乳桿菌I21被接種至一MRS培養盤上並於37℃下培養3天。細菌是以一為1μl無菌接種環從該培養盤刮下、接種至MRS肉湯中，並於37℃下生長1天以製備一
接種原。該接種原(30ml)隨後被加入至配於5L發酵槽中的3L MRS肉湯內，並於37℃下生長2天。在3000rpm下將該發酵肉湯離心15分鐘。上清液被收集並冷凍乾燥以製造出雷曼氏乳桿菌I21發酵產物。
ICR小鼠被用來作為實驗動物。氧嗪酸鉀(potassium oxonate)(一種尿酸酶抑制劑)被用來在該小鼠之血清內誘發一高位準之尿酸。小鼠被禁食1小時然後經由一餵食管被餵食食鹽水或氧嗪酸鉀(400mg/kg)。1小時之後，經氧嗪酸鉀處理的小鼠被餵食鹽水、異嘌呤醇(10mg/kg)或一如上述所製備之雷曼氏乳桿菌I21發酵產物(每隻小鼠150mg或200mg，其被再懸浮於食鹽水中)。每個實驗組及對照組各使用10隻動物。在1小時後犧牲該等動物並分析在牠們血清中的尿酸位準。結果顯示於下面表3中。
於此說明書揭示之所有特徵可以任何組合方式
進行組合。於此說明書中揭示的每個特徵可被一用作相同、等效或相似目的之替代特徵所替換。因此，除非另有明確說明，所揭示之每個特徵只是同屬系列之等效或相似特徵中的一個實施例。
從以上說明，一熟習此藝者可輕易地確定本發明之必要特徵，並且可作出本發明之各種改變及修飾以使其適應各種用法及條件，而不偏離其精神及範圍。因此，其它實施態樣也落入申請專利範圍內。
1.雷曼氏乳桿菌(Lactobacillus rhamnosus)I21
財團法人食品工業發展研究所、民國103年5月30日、BCRC 910635
1.雷曼氏乳桿菌I21
德國、DSMZ、2014年6月2日、DSM 28876
<110> 財團法人食品工業發展研究所
<120> 新穎的雷曼氏乳桿菌菌株(LACTOBACILLUS RHAMNOSUS)與其用於抑制黃嘌呤氧化酶及治療痛風之代謝產物
<130> 218003-0017U
<150> US 62/040,616
<151> 2014-08-22
<160> 2
<170> PatentIn version 3.5
<210> 1
<211> 1537
<212> DNA
<213> 雷曼氏乳桿菌
<220>
<221> misc_feature
<223> 菌株I21 16s rDNA
<400> 1
<210> 2
<211> 792
<212> DNA
<213> 雷曼氏乳桿菌
<220>
<221> misc_feature
<223> 菌株I21之部分DNAK序列
<400> 2
Claims (20)
- 一種用於降低一個體中之尿酸位準的方法，該方法包含於一培養基中培養雷曼氏乳桿菌以形成一組成物，以及將該組成物以一對於降低尿酸位準有效之量投予至一需要其之個體。
- 如請求項1之方法，其中該雷曼氏乳桿菌係雷曼氏乳桿菌I21，其寄存編號為DSM 28876。
- 如請求項1之方法，其中該個體患有痛風或高尿酸血症。
- 如請求項1之方法，進一步包含在該投予步驟之前從該組成物中移除雷曼氏乳桿菌。
- 如請求項1之方法，其中該組成物係口服、肌內、皮內、靜脈內、皮下、腹膜內、鼻內、黏膜投予。
- 如請求項1之方法，其中該培養基係MRS肉湯、牛奶或一果汁。
- 如請求項1之方法，進一步包含冷凍乾燥該組成物以形成一粉末。
- 一種用於降低一個體中之尿酸位準的組成物，該組成物包含雷曼氏乳桿菌之一代謝產物，其中該代謝產物係黃嘌呤氧化酶活性之一抑制劑。
- 如請求項8之組成物，其中該雷曼氏乳桿菌係雷曼氏乳桿菌I21，其寄存編號為DSM 28876。
- 如請求項8之組成物，其中該組成物中沒有雷曼氏乳桿菌。
- 如請求項8之組成物，進一步包含一選自由下列組成之群組中的藥學上可接受之賦形劑：一緩衝劑、一稀釋劑、一崩散劑、一結著劑、一黏著劑、一濕潤劑、一聚合物、一潤滑劑、一滑動劑及一調味劑。
- 如請求項8之組成物，進一步包含一選自由下列組成之群組中食物成分：一酸度調節劑、一防結塊劑、一抗氧化劑、一增積劑、一載體、一乳化劑、一增味劑、一包覆劑、一保存劑、一安定劑、一甜味劑、一增稠劑、一營養添加劑及一調味劑。
- 一種用於製造用以降低一個體中之尿酸位準之組成物的方法，該方法包含將一培養基接種雷曼氏乳桿菌，以及於該培養中培養雷曼氏乳桿菌以形成一組成物。
- 如請求項13之方法，其中該雷曼氏乳桿菌係雷曼氏乳桿菌I21，其寄存編號為DSM 28876。
- 如請求項13之方法，進一步包含從該組成物中移除雷曼氏乳桿菌。
- 如請求項13之方法，其中該培養基係MRS肉湯、牛奶或一果汁。
- 如請求項13之方法，進一步包含冷凍乾燥該組成物。
- 如請求項13之方法，進一步包含藉由巴斯德消毒法(pasteurization)、照射滅菌、高壓滅菌釜或過濾來將該組成物滅菌。
- 如請求項17之方法，其中該培養係於37℃下實行歷時2天。
- 如請求項19之方法，其中該移除步驟之前的一培養密度為1 x 109個細胞/ml。
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462040616P | 2014-08-22 | 2014-08-22 | |
| US62/040,616 | 2014-08-22 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| TW201625284A true TW201625284A (zh) | 2016-07-16 |
| TWI678208B TWI678208B (zh) | 2019-12-01 |
Family
ID=55347337
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW104127381A TWI678208B (zh) | 2014-08-22 | 2015-08-21 | 新穎的雷曼氏乳桿菌菌株（ｌａｃｔｏｂａｃｉｌｌｕｓ ｒｈａｍｎｏｓｕｓ）與其用於抑制黃嘌呤氧化酶及治療痛風之代謝產物 |
Country Status (3)
| Country | Link |
|---|---|
| US (2) | US9636368B2 (zh) |
| CN (1) | CN105497078B (zh) |
| TW (1) | TWI678208B (zh) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112481172A (zh) * | 2020-12-16 | 2021-03-12 | 江南大学 | 鼠李糖乳杆菌ccfm1130及其缓解治疗痛风的应用 |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3915565A3 (en) * | 2013-03-15 | 2022-03-16 | XORTX Therapeutics Inc. | Xanthine oxidase inhibitor formulations |
| KR20170110083A (ko) | 2014-12-23 | 2017-10-10 | 인털렉츄얼 프라퍼티 어쏘시에이츠, 엘엘씨 | 경피 투여를 위한 방법 및 제형 |
| TWI676684B (zh) * | 2017-06-15 | 2019-11-11 | 財團法人食品工業發展研究所 | 乳酸桿菌、使用其製備色素之方法、乳酸桿菌培養物與包括其之色素組成物 |
| US20190083386A1 (en) | 2017-09-15 | 2019-03-21 | Ampersand Biopharmaceuticals, Inc. | Methods and formulations for transdermal administration of buffering agents |
| CN108410761B (zh) * | 2018-03-06 | 2020-03-20 | 山东凤凰生物有限公司 | 一株具有降亚硝酸盐、抗氧化的鼠李糖乳杆菌及筛选分离方法 |
| WO2019203827A1 (en) * | 2018-04-19 | 2019-10-24 | Kibow Biotech Inc . | Composition and method for preventing or treating hyperuricemia or gout |
| CN109125361A (zh) * | 2018-09-26 | 2019-01-04 | 广州市健全家源信息科技有限公司 | 一种降低高尿酸和缓解痛风急性发作期症状的复合物 |
| CN110184209B (zh) * | 2019-04-24 | 2020-10-30 | 杭州娃哈哈科技有限公司 | 一株可降低血尿酸的鼠李糖乳杆菌 |
| CN110623182A (zh) * | 2019-10-10 | 2019-12-31 | 胡洁 | 一种用于治疗高尿酸及痛风的益生菌植物固体饮料 |
| CN110591988B (zh) * | 2019-11-01 | 2021-05-14 | 四川农业大学 | 鼠李糖乳杆菌753及其应用、青贮饲料添加剂、青贮饲料 |
| TWI730679B (zh) * | 2020-03-18 | 2021-06-11 | 康品科技有限公司 | 具降尿酸能力的胚芽乳酸桿菌bfa-la04菌株及其用途 |
| CN111826315B (zh) * | 2020-07-20 | 2022-04-01 | 广东南芯医疗科技有限公司 | 一株鼠李糖乳杆菌nx-2及其在制备降尿酸药物中的应用 |
| CN115843254A (zh) * | 2020-07-24 | 2023-03-24 | 贝奥治疗公司 | 微生物疗法 |
| CN112725216B (zh) * | 2020-11-10 | 2022-07-08 | 扬州大学 | 一株高效降解嘌呤的鼠李糖乳杆菌YZULr026及其应用 |
| CN112574917B (zh) * | 2020-12-16 | 2022-08-09 | 无锡特殊食品与营养健康研究院有限公司 | 一株缓解高尿酸血症的鼠李糖乳杆菌ccfm1131 |
| CN114149947B (zh) * | 2021-12-02 | 2022-09-27 | 山东宝来利来生物工程股份有限公司 | 一株产尿酸氧化酶并抑制黄嘌呤氧化酶的植物乳杆菌及其应用 |
| CN115109734B (zh) * | 2022-08-30 | 2022-12-13 | 北京量化健康科技有限公司 | 一株具有缓解高尿酸功能敏捷乳杆菌b13t4及其应用 |
| CN116694530B (zh) * | 2023-06-28 | 2023-11-07 | 北京量化健康科技有限公司 | 一种乳杆菌组合物及其应用 |
| CN116622593B (zh) * | 2023-07-21 | 2023-10-20 | 中国农业科学院农产品加工研究所 | 一株发酵用的副干酪乳杆菌及其制备抗风排酸酵素的发酵工艺 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3582728A (en) * | 1969-03-06 | 1971-06-01 | Johnson Service Co | Capacitance humidity sensing element |
| EP0624074A1 (en) * | 1992-02-01 | 1994-11-17 | The Victoria University Of Manchester | Electrode |
| CA2416120A1 (en) * | 2000-07-17 | 2002-01-24 | Svend Laulund | Methods and formulations with probiotic microorganisms and medicaments |
| US9655932B2 (en) | 2002-03-13 | 2017-05-23 | Kibow Biotech, Inc. | Composition and method for preventing or treating gout or hyperuricemia |
| US20040208863A1 (en) * | 2003-01-30 | 2004-10-21 | James Versalovic | Anti-inflammatory activity from lactic acid bacteria |
| US20040185032A1 (en) * | 2003-03-18 | 2004-09-23 | David Burrell | Compositions and methods for treating colic |
| JPWO2004112809A1 (ja) | 2003-06-24 | 2006-07-20 | 大塚製薬株式会社 | 血清尿酸低減組成物 |
| US20090136468A1 (en) * | 2004-10-29 | 2009-05-28 | N.V. Nutricia | Peri-operative composition comprising lactobacillus rhamnosus |
| EP2476747B1 (en) * | 2007-11-29 | 2014-09-03 | Meiji Co., Ltd | Lactic acid bacteria having action of lowering blood uric acid level |
| CA2707187C (en) * | 2007-11-30 | 2016-05-31 | Meiji Dairies Corporation | Lactic acid bacterium having effect of lowering blood uric acid level |
| US9737575B2 (en) * | 2008-11-28 | 2017-08-22 | University Of Otago | Use of lactic acid bacteria to treat or prevent eczema |
| PL2457576T3 (pl) | 2010-11-29 | 2021-04-06 | Eurochit Danuta Kruszewska | Szczep Lactobacillus reuteri do stosowania medycznego i weterynaryjnego w profilaktyce oraz w leczeniu zespołu metabolicznego lub infekcji |
| CN102370859A (zh) | 2011-10-02 | 2012-03-14 | 莫寿科 | 一种治疗痛风的外敷药及其制备方法 |
| KR101321611B1 (ko) | 2012-02-29 | 2013-10-23 | (주)그린팜테크 | 구절초 및 진주조개껍질을 함유한 기능성 식초 및 이의 제조방법 |
-
2015
- 2015-08-11 US US14/823,585 patent/US9636368B2/en active Active
- 2015-08-21 TW TW104127381A patent/TWI678208B/zh active
- 2015-08-22 CN CN201510519096.7A patent/CN105497078B/zh active Active
-
2017
- 2017-04-10 US US15/483,575 patent/US20170216376A1/en not_active Abandoned
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112481172A (zh) * | 2020-12-16 | 2021-03-12 | 江南大学 | 鼠李糖乳杆菌ccfm1130及其缓解治疗痛风的应用 |
Also Published As
| Publication number | Publication date |
|---|---|
| US20160051602A1 (en) | 2016-02-25 |
| CN105497078B (zh) | 2021-02-09 |
| CN105497078A (zh) | 2016-04-20 |
| TWI678208B (zh) | 2019-12-01 |
| US9636368B2 (en) | 2017-05-02 |
| US20170216376A1 (en) | 2017-08-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TWI678208B (zh) | 新穎的雷曼氏乳桿菌菌株（ｌａｃｔｏｂａｃｉｌｌｕｓ ｒｈａｍｎｏｓｕｓ）與其用於抑制黃嘌呤氧化酶及治療痛風之代謝產物 | |
| EP2305838B1 (en) | Bifidobacteria that produces folic acid, food composition and use of said bifidobacteria | |
| JP6483653B2 (ja) | 乳酸菌および／またはビフィズス菌の生残性向上剤 | |
| CN110923166A (zh) | 动物双歧杆菌乳亚种jmcc0025、其分离纯化方法及应用 | |
| RU2758109C2 (ru) | Бактерия lactobacillus rhamnosus для лечения, например, бактериального вагиноза | |
| EP1972208A1 (en) | Composition for improving intestinal microflora | |
| EP2568815B1 (en) | Synergistic fermentation of lactobacillus rhamnosus and lactobacillus paracasei subsp paracasei | |
| CN110564638A (zh) | 一株具有益生特性的罗伊氏乳杆菌及其用途 | |
| EP2828375A1 (en) | Gaba-producing culturable bacteria derived from the human gastrointestinal tract | |
| TWI719947B (zh) | 新穎的醋酸桿菌菌株及葡糖酸醋酸桿菌菌株與其等用於抑制黃嘌呤氧化酶之代謝產物 | |
| JP2013534142A (ja) | ビタミンｋ２高生産性ラクトコッカス・ラクティス株 | |
| JP2013537427A (ja) | ビタミンｋ２高生産性ラクトコッカス・ラクティス株 | |
| KR100954882B1 (ko) | 조류 인플루엔자 바이러스 감염억제 효과를 가지는 신규 유산균 및 이를 포함하는 조성물 | |
| US9867857B2 (en) | Acetobacter and gluconacetobacter strains and their metabolites for use in inhibiting xanthine oxidase | |
| JP2014522667A (ja) | Ｈ．ピロリ株の上皮細胞への付着を阻害することが可能な新規のｌ．ブルガリクス株 | |
| JP6654639B2 (ja) | 血中トリプトファン濃度上昇抑制剤 | |
| KR100973977B1 (ko) | 신규한 락토바실러스 속 미생물 및 이의 용도 | |
| EP3313424B1 (en) | Lactobacillus rhamnosus bacterium for treatment of e.g. bacterial vaginosis | |
| Kim et al. | In vitro characterization study of Bacillus mojavensis KJS-3 for a potential probiotic | |
| CN114774314B (zh) | 一株鼠李糖乳杆菌菌株LRa05及其用途与产品 | |
| JP5980785B2 (ja) | 新規ビフィズス菌及びその利用 | |
| CN117917475A (zh) | 一种调节肠道菌群的植物乳植杆菌p16及其应用、产品和方法 | |
| KR20220160773A (ko) | 항염증 활성이 우수한 김치 유래 신균주 락토바실러스 퍼멘텀 및 이를 포함하는 염증성 질환의 예방 또는 치료용 조성물 | |
| TW200400261A (en) | Lactobacillus rhamnosus strain and uses thereof |